Vonaprazan CAS 503612-47-3 Raw Materials

CAS: 503612-47-3

MF: C21H20FN3O6S

Specification​: 99% min Vonaprazan Powder

Sample:  Vonaprazan Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Vonaprazan Powder Usage and Synthesis:

Vonaprazan is a medication used to treat gastroesophageal reflux disease (GERD) and other related conditions such as heartburn and acid indigestion. It works by reducing the production of stomach acid, which can help alleviate symptoms of GERD and prevent damage to the esophagus.

Vonaprazan belongs to a class of drugs called proton pump inhibitors (PPIs), which are commonly used to treat acid-related disorders. Unlike other PPIs, vonaprazan has a unique mechanism of action that allows it to bind to and inhibit the proton pump more effectively, resulting in faster and longer-lasting acid suppression.

Vonaprazan is available in tablet form and is typically taken once a day, with or without food. It is important to follow the dosage instructions provided by your healthcare provider and to avoid taking more than the recommended amount.

As with any medication, vonaprazan may cause side effects, including headache, diarrhea, nausea, and abdominal pain. It may also increase the risk of certain infections and bone fractures, especially with long-term use. If you experience any unusual symptoms or side effects while taking vonaprazan, be sure to contact your healthcare provider right away.

Pharmacokinetics of Vonaprazan Powder:

Vonaprazan fumarate (TAK-438) is a potassium ion (K+) competitive acid blocker (P-CAB), a reversible proton pump inhibitor, which, upon entry into the body, terminates the secretion of gastric acid by inhibiting the combination of K+ and H+-K+-ATPase (proton pump) in the final step of acid secretion in the gastric lining cells, resulting in a strong and long-lasting inhibition of gastric acid secretion.
TAK-438 is stable in acid, and the fast-acting formulation is readily available, eliminating the need for optimized formulation design (e.g., enteric coating), and the difference in the starting dose of efficacy among patients is not significant. Based on these advantages, TAK-438 is expected to be a new therapeutic agent to solve the current problems in the treatment of acid-related diseases.

Clinical Application of Vonaprazan Powder:

Vonora fumarate tablet is a novel acid suppressant originally developed by Takeda Pharmaceutical for the treatment of acid-related diseases. This included RefluxEsophagitis (RE), gastric and duodenal ulcers, prevention of recurrence of gastric or duodenal ulcers during treatment with low-dose aspirin or non-steroidal anti-inflammatory drugs, and eradication of H. pylori.

Eradication of Helicobacter pylori, auxiliary treatment of the following diseases: gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, early gastric cancer, helicobacter pylori infectious gastritis.

Vonaprazan Powder is a raw material for the treatment of erosive esophagitis,  gastric ulcer and duodenal ulcer. Vonaprazan Raw Materials is a medication used to treat gastroesophageal reflux disease  (GERD) and other related  conditions such as heartburn and acid indigestion. Vonaprazan works by reducing the  production of stomach acid,  which can help alleviate symptoms of GERD and prevent damage to the esophagus.

China Pharmaceutical Ingredients Factory